1. Introduction
Osteosarcoma, the most prevalent primary malignant bone tumor, demonstrates a bimodal age distribution with peaks at 18 and 60 years of age, exhibiting a slightly higher incidence in males compared to females[
1]. Although surgical interventions, neoadjuvant, and adjuvant chemotherapy have led to significant improvements in patient survival since the 1980s, the prognosis for osteosarcoma remains stagnant[
2]. Thus, a comprehensive understanding of the molecular mechanisms driving osteosarcoma is crucial for developing novel preventive and therapeutic strategies.
Regulated cell death (RCD) refers to a controlled form of cell death that occurs in organisms[
3]. Unlike non-regulated forms of cell death, RCD is a highly organized process regulated by multiple signaling pathways and factors. RCD not only plays a vital role in organism development and cellular homeostasis but also contributes to the pathogenesis of various diseases, including cancer[
4]. Disulfidptosis is a form of RCD induced by oxidative stress and lipid peroxidation resulting from excessive intracellular free iron (Fe2+)[
5]. The uptake of cystine mediated by solute carrier family 7 member 11 (SLC7A11) is pivotal in promoting glutathione synthesis, inhibiting oxidative stress, and regulating ferroptosis. However, recent studies have shown that while SLC7A11-mediated cystine transport can inhibit ferroptosis, it does not prevent cell death under glucose deprivation conditions[
6,
7,
8]. Additionally, the conversion of cystine imported by SLC7A11 to cysteine heavily relies on the generation of reduced nicotinamide adenine dinucleotide phosphate (NADPH) through the glucose-6-phosphate dehydrogenase (G6PD)-dependent pentose phosphate pathway [
9]. Based on this, a recent study revealed a mechanism in which cells expressing high levels of SLC7A11 accumulate abnormal levels of cysteine and other disulfides under glucose-starvation conditions, leading to disulfide stress and rapid cell death. This newly identified form of cell death is termed disulfidptosis[
10]. Although research on disulfidptosis is still in its nascent stage, this form of cell death holds promise for developing new avenues for the treatment of osteosarcoma by targeting cancer metabolism.
The tumor microenvironment (TME) plays a crucial role in tumor development and treatment. Investigating the TME provides insights into the mechanisms of tumor progression and offers new strategies for cancer therapy[
11]. Advanced techniques for single-cell analysis of cell communication provide valuable information about cell types, subtypes, intercellular interactions, expression and secretion of signaling molecules, as well as spatial and temporal dynamics of communication. These details contribute to our understanding of the mechanisms and regulatory networks underlying cell communication within the TME, laying the foundation for the development of precise therapeutic strategies and immunotherapies[
12]. Previous studies have utilized single-cell sequencing technologies to identify major cell types within the TME of osteosarcoma, including osteoblastic osteosarcoma cells, proliferating osteoblastic osteosarcoma cells, chondroblastic osteosarcoma cells, osteoclasts, tumor-infiltrating lymphocytes (TILs, including T cells and NK cells), myeloid cells, fibroblasts, mesenchymal stem cells (MSCs), stromal cells, myocytes, and endothelial cells[
13]. These findings establish a foundation for further research. Additionally, metabolic treatments may impact non-tumor cells within the TME, particularly metabolic inhibition of immune cells, which can diminish their anti-tumor efficacy[
14]. Similarly, the development of disulfidptosis induction through GLUT inhibition faces challenges in drug development[
15]. Therefore, investigating the role of disulfidptosis in the TME may contribute to its clinical translation and the identification of potential immunotherapeutic strategies. However, to date, no study has focused on the interaction between disulfidptosis-related subtypes in the TME and tumor cells.
In this study, we conducted an analysis of 100,987 cells from 11 patients to investigate the impact of disulfidptosis on major immune cells in the TME of osteosarcoma, including fibroblasts, macrophages, and tumor-infiltrating lymphocytes (TILs). We employed Non-negative Matrix Factorization (NMF) to classify the major immune cell populations and define multiple disulfidptosis-related NMF clusters. Fourteen disulfidptosis-related genes were used to delineate the NMF clusters[
15]. The results revealed extensive and specific communication between different disulfidptosis-related subtypes in the TME and their significant associations with immune features, immunotherapy response, cellular transcription, and prognosis. To our knowledge, this is the first study to elucidate the communication between osteosarcoma cells and cells in the TME by classifying tumor microenvironment subpopulations using NMF. This study contributes to a better understanding of the underlying mechanisms of osteosarcoma development and advances in immunotherapy.
4. Discussion
Over the years, extensive research has been conducted to investigate the regulatory cell death (RCD) pathways that influence tumor formation and development[
27,
28,
29]. In recent years, there has been a focus on investigating the remodeling of tumor RCD pathways within the tumor microenvironment (TME) to activate pro-inflammatory signals and immunogenicity necessary for anti-tumor immune responses[
30]. However, limited attention has been given to exploring the impact of PCD pathways in immunocytes on tumors. In this study, we comprehensively examined the expression of disulfidptosis-related genes in major cell types within the osteosarcoma microenvironment and elucidated the specific associations between disulfidptosis-related subtypes within the TME and osteosarcoma tumors. This unique perspective provides a deeper understanding of how the disulfidptosis pathways of different cellular components within the TME influence the prognosis and outcomes of individual osteosarcoma patients.
Tumor cells constitute the main component of osteosarcoma tissue and play a crucial role in determining patient prognosis and the efficacy of targeted therapies[
31]. Additionally, the infiltration of immune cells in osteosarcoma tissue contributes to the complex immune microenvironment that supports the proliferation and invasion of tumor cells[
32]. Therefore, it is of great significance to study the major immune cells in the TME and their intricate communication with osteosarcoma cells to develop advanced immunotherapeutic approaches. Notably, lymphocyte infiltration occurs in different regions and subgroups of osteosarcoma, involving multiple molecules with diverse roles in anti-tumor immune responses[
33,
34,
35]. Tumor-associated macrophages (TAMs) have also garnered attention as potential targets to enhance immunotherapy for osteosarcoma[
36]. While clinical trials targeting tumor-associated fibroblasts (CAFs) have had limited success, CAFs remain promising therapeutic targets in cancer treatment[
37]. Our study reveals distinct disulfidptosis regulatory patterns in these three components of the tumor microenvironment, highlighting their extensive communication with osteosarcoma cells. Cellchat analysis identified various ligand-receptor pairs, such as LGALS9-CD44, LGALS9-CD45, PTN-NCL, MDK-NCL, MDK-LRP1, SPP1-CD44, MIF-CD74-CD44, and MIF-CD74-CXCR4, which mediate the communication between disulfidptosis-related subtypes and osteosarcoma cells.
The current tumor-centric treatment approach often fails to eradicate tumors due to metastasis, drug resistance, and the resistant tumor microenvironment[
38,
39]. Increasing evidence highlights the critical role of the TME in promoting cancer development, leading researchers to recognize the TME as a key factor in the successful treatment of malignant tumors[
40]. Among the diverse stromal components in the TME, CAFs have emerged as major therapeutic targets in various cancer types[
41]. To better understand the heterogeneity of CAFs, we classified pan-CAF into five subtypes based on molecular features, including pan-myCAFs, pan-dCAFs, pan-iCAFs, pan-nCAFs, and pan-pCAFs. Specific pan-CAF subtypes have been associated with immune checkpoint blockade (ICB) resistance in different tumors. Our study revealed correlations between distinct disulfidptosis-related fibroblast subtypes and various pan-CAF subtypes. Furthermore, we found that disulfidptosis-related fibroblast subtypes exhibited stronger communication with osteosarcoma cells. Specifically, the CAPZB+CAF subtype showed close associations with pan-myCAF and several pro-inflammatory factors, such as CFD, CFI, C3, C7, CXCL14, CXCL12, among others. Moreover, we identified distinct and specific patterns of cytokine expression among different categories of CAFs. Therefore, we hypothesize that within the osteosarcoma tumor microenvironment, the CAPZB+CAF subtype primarily secretes pro-inflammatory cytokines and plays a crucial role in remodeling the immune microenvironment. Consequently, disulfidptosis-related fibroblast subtypes may mediate the remodeling of the tumor microenvironment and potentially correlate with poor prognosis, tumor growth, and invasion[
42,
43,
44].
Currently, there is a growing recognition of the pivotal role of programmed cell death (PCD) in the tumor microenvironment (TME)[
45]. PCD in certain tumors can elicit immune responses in the TME by releasing cellular components such as pro-inflammatory cytokines and damage-associated molecular patterns[
46]. Conversely, PCD in immune cells can directly disrupt anti-tumor immunity within the TME[
47,
48]. Therefore, a comprehensive assessment of PCD in different cell types within the TME is crucial for devising effective tumor treatment strategies. In our study, we identified the INF2+Mac subtype through non-negative matrix factorization (NMF) classification, which showed associations with multiple metabolic pathways. Notably, the disulfidptosis-related macrophage subtypes exhibited a closer relationship with metabolism compared to other subtypes. This finding sheds light on the significant role of disulfidptosis in guiding and regulating macrophage metabolism. The metabolic pathways of myeloid cells, represented by macrophages, and lymphocytes, represented by T cells, play pivotal roles in immune activation[
49]. Moreover, survival analysis demonstrated a positive impact of the disulfidptosis-related macrophage subtype on overall survival. The INF2+Mac subtype, representing the disulfidptosis-related subtypes, exhibited significant activation of metabolic pathways. The characteristic genes of the INF2+Mac subtype were notably enriched in sulfur metabolism, steroid biosynthesis, starch and sucrose metabolism, oxidative phosphorylation, and other metabolic pathways. Additionally, our study found no significant differences in the distribution of disulfidptosis-related subtypes between M1 and M2 macrophages. Furthermore, we identified extensive associations between four types of infiltrating lymphocytes mediated by disulfidptosis and tumors. Different subtypes exhibited distinct expression patterns of specific cytokines.
To gain further insights into the heterogeneity of gene regulatory networks underlying cellular heterogeneity, we performed transcription factor analysis at the single-cell level. The results revealed distinct transcriptional characteristics among various disulfidptosis-related subtypes, including cancer-associated fibroblasts (CAFs), infiltrating lymphocytes, and macrophages. Several transcription factors, such as JUND, FOS, and IRF1[
50,
51,
52], were found to be involved in the activation of PCD. However, further research is required to elucidate the specific transcription factors involved in the disulfidptosis process. In summary, similar to other forms of PCD, disulfidptosis-related cell subtypes can regulate different transcription factor networks to reshape the TME. Cell-cell communication analysis using Cellchat unveiled specific interactions between disulfidptosis-related subtypes of various cell populations and osteosarcoma cells. Moreover, within the CAFs subgroup, disulfidptosis-related subtypes exhibited more extensive cellular communication with osteosarcoma cells, suggesting that the disulfidptosis mode of CAFs may contribute to TME inhibition.
To gain deeper insights into the broader implications of disulfidptosis modes on the tumor microenvironment (TME), we utilized publicly available RNA-seq data to score and evaluate these subtypes in relation to prognosis and response to immunotherapy. The analysis revealed significant prognostic implications of disulfidptosis-related TME subtypes in osteosarcoma, with the subtypes of cancer-associated fibroblasts (CAFs) exhibiting the most pronounced variations in immunotherapy response. These findings were further validated in an independent immunotherapy cohort of bladder cancer (BLCA). Collectively, these results highlight the potential value of disulfidptosis mode in the treatment of osteosarcoma, underscoring its critical significance for subtype investigations within the osteosarcoma TME.
As the first systematic analysis of the impact of disulfidptosis-induced cell death mode in the TME, our conclusions are not without limitations. In addition to the inherent noise and errors in single-cell data, our findings require further validation using a larger clinical sample size. Nevertheless, our study offers a novel perspective on unraveling the characteristics of disulfidptosis-induced cell death in the TME, advancing our understanding of this specific programmed cell death mode, and providing new insights for other domains within the life sciences.